India's Draft Drugs, Medical Devices and Cosmetics Bill 2026: Key Changes for Manufacturers

This episode covers India's draft Drugs, Medical Devices and Cosmetics Bill 2026, circulated for feedback on August 7, 2026. We discuss its proposal to replace the 1940 Drugs and Cosmetics Act, creating a separate regulatory framework for medical devices, establishing a Medical Devices Technical Advisory Board (MDTAB), and enhancing enforcement powers. We explore the impact on manufacturers and provide practical steps for regulatory teams to prepare for this significant shift in India's MedTech landscape. Key Questions: - What is the new Drugs, Medical Devices and Cosmetics Bill 2026 in India? - How will this bill change the regulation of medical devices in India? - Why is separating device regulation from drug regulation a critical development? - What is the proposed role of the Medical Devices Technical Advisory Board (MDTAB)? - Which companies will be most affected by these new regulations? - What new enforcement powers are being introduced for the regulator? - How does this draft bill impact manufacturers currently operating under the 1940 Act? - What practical steps should regulatory and quality teams take now to prepare? - When can manufacturers expect these changes to come into effect? - How does this align India's regulations with global standards? Sources: - https://gdcclasses.com/drugs-medical-devices-cosmetics-bill-2026/ - https://www.biospectrumindia.com/news/25/24933/9th-india-medical-device-2026-opens-in-new-delhi-to-focus-on-developing-india-as-global-medtech-hub.html - https://www.operonstrategist.com/cdsco-sanctions-1500-new-posts-unveils-key-regulatory-reforms-for-medical-devices/ - https://www.theindianpractitioner.com/new-drugs-bill-seeks-to-rename-dcgi-bring-medical-devices-under-law/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies targeting the Indian market, our experts offer end-to-end support, from developing a regulatory strategy aligned with the new Drugs, Medical Devices and Cosmetics Bill 2026 to managing technical dossier submissions and acting as your local authorized representative. We leverage advanced AI and in-country expertise to help you navigate regulatory transitions efficiently, ensuring your products achieve and maintain compliance. To learn more about how we can accelerate your entry into over 30 global markets, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.